Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
India
Pharma
Granules receives Form 483 over poor document controls and more
From truckloads of torn documents to avian incursions, Granules' new manufacturing reprimand from the FDA is alarming no matter which way you read it.
Fraiser Kansteiner
Sep 19, 2024 10:11am
Zydus hit with FDA warning letter flagging glass contamination
Sep 11, 2024 11:42am
FDA issues Form 483s to Japanese, Indian drugmakers
Sep 10, 2024 8:50am
API maker Global Calcium gets hit with FDA Form 483
Aug 29, 2024 11:52am
FDA rebukes troubled Eugia production site with a warning letter
Aug 19, 2024 8:10am
Vivint Pharma to spend $48M to build injectables plant in India
Aug 9, 2024 8:45am
